Ann Arbor-based University of Michigan has opened a first-of-its-kind facility dedicated to histotripsy — a noninvasive, ultrasound-based cancer treatment.
The $10 million University of Michigan Histotripsy Center is available for researchers both inside and outside the university, according to a Sept. 11 news release.
As the equipment is not yet commercially available, researchers can come to the center to perform tests. University of Michigan histotripsy experts can also travel with the equipment to research locations within the U.S., the release said.
The first phase of the histotripsy center’s operations will focus on cancer and neurology research and strengthening histotripsy education. The second phase will focus on training clinicians and conducting trial studies.
Histotripsy was invented at the University of Michigan and received FDA authorization for the treatment of liver tumors in 2023. Since then, more than 130 histotripsy systems have been used to treat over 5,000 patients across the globe, the release said.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
